Financial Post
New data highlights the safety and efficacy of a new outpatient self-administered therapy intended to assist in the management of fluid overload in CHF, liver, and kidney disease patients HENDERSON, Nev. — Corstasis Therapeutics Inc., a clinical-stage biotechnology company pioneering outpatient therapies for fluid overload (edema) associated with congestive heart failure (CHF…
Read More
Corstasis Therapeutics to Present Pivotal Trial Data on Novel Bumetanide Nasal Spray at American Heart Association Scientific Sessions 2024
Business Wire
22:23
New data highlights the safety and efficacy of a new outpatient self-administered therapy intended to assist in the management of fluid overload in CHF, liver, and kidney disease patients HENDERSON, Nev. — Corstasis Therapeutics Inc., a clinical-stage biotechnology company pioneering outpatient therapies for fluid overload (edema) associated with congestive heart failure (CHF…
